+ All Categories
Home > Documents > Editorial New Diagnostic and Therapeutic Tools for Thyroid Cancer · 2020. 1. 20. · of...

Editorial New Diagnostic and Therapeutic Tools for Thyroid Cancer · 2020. 1. 20. · of...

Date post: 14-May-2021
Category:
Upload: others
View: 1 times
Download: 0 times
Share this document with a friend
2
Hindawi Publishing Corporation International Journal of Endocrinology Volume 2013, Article ID 312378, 1 page http://dx.doi.org/10.1155/2013/312378 Editorial New Diagnostic and Therapeutic Tools for Thyroid Cancer Eleonore Fröhlich, 1 Richard Wahl, 2 Barbara Czarnocka, 3 and Leonidas Duntas 4 1 Center for Medical Research, Medical University of Graz, 8010 Graz, Austria 2 Department of Medicine IV (Diabetology, Endocrinology, Angiology, Nephrology, and Clinical Chemistry), Medical Clinic, 72076 Tuebingen, Germany 3 Medical Center of Postgraduate Education, 01-813 Warsaw, Poland 4 Endocrine Unit, Evgenidion Hospital, University of Athens Medical School, 11528 Athens, Greece Correspondence should be addressed to Eleonore Fr¨ ohlich; [email protected] Received 20 October 2013; Accepted 20 October 2013 Copyright © 2013 Eleonore Fr¨ ohlich et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. yroid cancer is the commonest endocrine malignancy but represents only 1% of all cancers. Although the prognosis of differentiated thyroid cancer is good, the survival time of anaplastic and of medullary thyroid cancer is still very short. More precise diagnosis with better stratification of patients and identification of risk patients may improve the prognosis of thyroid cancer. Treatment of thyroid cancer is multidis- ciplinary and involves endocrinologists, nuclear medicine specialists, and surgeons. e spectrum of contributions to this special issue in International Journal of Endocrinology is well reflecting this situation. e contributions to this special issue, two reviews and three studies, report mainly on laboratory and imaging tech- niques to improve diagnosis in thyroid cancer. J. Hannallah et al. emphasize the multimodal approach in diagnosis and managing patients with poorly differentiated thyroid cancer in their review. e identification of poorly differentiated thyroid cancer has been complicated by the lack of clear criteria for diagnosis. A panel of histological, immunohis- tochemical, and genetic markers and clinical parameters is listed which are typical for this thyroid carcinoma entity. e value of current treatment possibilities is critically discussed. In the paper review by G. Treglia et al. the role of Fluorine-18-Fluorodeoxyglucose positron emission tomo- graphy in aggressive subtypes of different thyroid cancer types (H¨ urthle cell, anaplastic, poorly differentiated, more aggressive histological subtypes of differentiated thyroid cancer, and metastases) is discussed. FDG-PET-positivity in radio-iodine-refractory differentiated thyroid cancer appears to predict more aggressive tumor progression. Data on imag- ing of medullary thyroid carcinoma lesions using glucagon- like peptide 1 by [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]- exendin-4 are presented by D. Pach et al. Radioactively labeled GLP-1 analogues are successfully used in patients with insulinoma but the diagnostic value in medullary thyroid cancer is not clear. According to the first preliminary data, the analogues may possess a confirmatory role in lesions where inconsistent results are obtained with other imaging procedures. S. H. Hsieh et al. in their study identified male gender as prognostic parameter for higher recurrence in papillary thyroid cancer in stages II–IV. e study by B. C. Ahn et al., by contrast, deals with a very established clinical test, the measurement of serum thyroglobulin levels, for the identification of recurrent lesions in differentiated thyroid cancer. e importance of patients’ antithyroglobulin levels in the calculation of thyroglobulin levels is addressed. e identification of potentially aggressive subtypes of thyroid cancer and the early detection of recurrent lesions play key roles in the managing of the patient. By compiling these papers, we hope to add some knowledge with respect to screening and postoperative care particularly of the more aggressive thyroid cancer types. Eleonore Fr¨ ohlich Richard Wahl Barbara Czarnocka Leonidas Duntas brought to you by CORE View metadata, citation and similar papers at core.ac.uk provided by Crossref
Transcript
Page 1: Editorial New Diagnostic and Therapeutic Tools for Thyroid Cancer · 2020. 1. 20. · of Fluorine--Fluorodeoxyglucosepositronemission tomo-graphy in aggressive subtypes of di erent

Hindawi Publishing CorporationInternational Journal of EndocrinologyVolume 2013, Article ID 312378, 1 pagehttp://dx.doi.org/10.1155/2013/312378

EditorialNew Diagnostic and Therapeutic Tools for Thyroid Cancer

Eleonore Fröhlich,1 Richard Wahl,2 Barbara Czarnocka,3 and Leonidas Duntas4

1 Center for Medical Research, Medical University of Graz, 8010 Graz, Austria2 Department of Medicine IV (Diabetology, Endocrinology, Angiology, Nephrology, and Clinical Chemistry),Medical Clinic, 72076 Tuebingen, Germany

3Medical Center of Postgraduate Education, 01-813 Warsaw, Poland4 Endocrine Unit, Evgenidion Hospital, University of Athens Medical School, 11528 Athens, Greece

Correspondence should be addressed to Eleonore Frohlich; [email protected]

Received 20 October 2013; Accepted 20 October 2013

Copyright © 2013 Eleonore Frohlich et al. This is an open access article distributed under the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properlycited.

Thyroid cancer is the commonest endocrine malignancy butrepresents only 1% of all cancers. Although the prognosisof differentiated thyroid cancer is good, the survival time ofanaplastic and of medullary thyroid cancer is still very short.More precise diagnosis with better stratification of patientsand identification of risk patients may improve the prognosisof thyroid cancer. Treatment of thyroid cancer is multidis-ciplinary and involves endocrinologists, nuclear medicinespecialists, and surgeons. The spectrum of contributions tothis special issue in International Journal of Endocrinology iswell reflecting this situation.

The contributions to this special issue, two reviews andthree studies, report mainly on laboratory and imaging tech-niques to improve diagnosis in thyroid cancer. J. Hannallahet al. emphasize the multimodal approach in diagnosis andmanaging patients with poorly differentiated thyroid cancerin their review. The identification of poorly differentiatedthyroid cancer has been complicated by the lack of clearcriteria for diagnosis. A panel of histological, immunohis-tochemical, and genetic markers and clinical parameters islisted which are typical for this thyroid carcinoma entity.The value of current treatment possibilities is criticallydiscussed. In the paper review by G. Treglia et al. the roleof Fluorine-18-Fluorodeoxyglucose positron emission tomo-graphy in aggressive subtypes of different thyroid cancertypes (Hurthle cell, anaplastic, poorly differentiated, moreaggressive histological subtypes of differentiated thyroidcancer, and metastases) is discussed. FDG-PET-positivity inradio-iodine-refractory differentiated thyroid cancer appears

to predict more aggressive tumor progression. Data on imag-ing of medullary thyroid carcinoma lesions using glucagon-like peptide 1 by [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 are presented by D. Pach et al. RadioactivelylabeledGLP-1 analogues are successfully used in patients withinsulinoma but the diagnostic value in medullary thyroidcancer is not clear. According to the first preliminary data,the analogues may possess a confirmatory role in lesionswhere inconsistent results are obtained with other imagingprocedures. S. H. Hsieh et al. in their study identified malegender as prognostic parameter for higher recurrence inpapillary thyroid cancer in stages II–IV. The study by B. C.Ahn et al., by contrast, deals with a very established clinicaltest, the measurement of serum thyroglobulin levels, for theidentification of recurrent lesions in differentiated thyroidcancer. The importance of patients’ antithyroglobulin levelsin the calculation of thyroglobulin levels is addressed.

The identification of potentially aggressive subtypes ofthyroid cancer and the early detection of recurrent lesionsplay key roles in the managing of the patient. By compilingthese papers, we hope to add some knowledge with respectto screening and postoperative care particularly of the moreaggressive thyroid cancer types.

Eleonore FrohlichRichard Wahl

Barbara CzarnockaLeonidas Duntas

brought to you by COREView metadata, citation and similar papers at core.ac.uk

provided by Crossref

Page 2: Editorial New Diagnostic and Therapeutic Tools for Thyroid Cancer · 2020. 1. 20. · of Fluorine--Fluorodeoxyglucosepositronemission tomo-graphy in aggressive subtypes of di erent

Submit your manuscripts athttp://www.hindawi.com

Stem CellsInternational

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

MEDIATORSINFLAMMATION

of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Behavioural Neurology

EndocrinologyInternational Journal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Disease Markers

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

BioMed Research International

OncologyJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Oxidative Medicine and Cellular Longevity

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

PPAR Research

The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014

Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Journal of

ObesityJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Computational and Mathematical Methods in Medicine

OphthalmologyJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Diabetes ResearchJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Research and TreatmentAIDS

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Gastroenterology Research and Practice

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Parkinson’s Disease

Evidence-Based Complementary and Alternative Medicine

Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com


Recommended